Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation: An economic perspective

Archives of Internal Medicine

Volumn 157, Issue 3, 1997, Pages 298-303

  Hull, Russell D ^a,b   Raskob, Gary E ^c   Pineo, Graham F ^a,b   Feldstein, William ^b   Rosenbloom, David ^d   Gafni, Amirain ^e   Green, David ^f   Feinglass, Joseph ^g   Trowbridge, Arthur A ^h   Gregory Elltott, C ⁱ   Lerner, Robert G ^j   Brant, Rollin ^a,b  

^a Faculty of Medicine   (United States)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF OKLAHOMA   (United States)

^d Department of Medicine ^*  (United States)

^e MCMASTER UNIVERSITY   (Canada)

^f REHABILITATION INSTITUTE OF CHICAGO   (United States)

^g NORTHWESTERN UNIVERSITY   (United States)

^h SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

ⁱ LDS HOSPITAL   (United States)

^j NEW YORK MEDICAL COLLEGE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN; TINZAPARIN; WARFARIN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; FEMALE; HEPARINIZATION; HIP ARTHROPLASTY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMPLANTATION; KNEE ARTHROPLASTY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 17544388644     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.157.3.298     Document Type: Article

References (40)

1. Harris, WH, Sledge CB. Total hip and total knee replacement. N Engl J Med. 1990;323:725-731, 801-807.
2. Coventry MB, Nolan DR, Beckenbaugh RD. 'Delayed' prophylactic anticoagulation: a study of results and complications in 2012 total hip arthroplasties. J Bone Joint Surg Am. 1973;55:1487-1492.
3. Johnson R, Green JR, Charnley J. Pulmonary embolism and its prophylaxis following the Charnley total hip replacement. Clin Orthop. 1977;127:123-132.
4. Stulberg BN, Insall JN, Williams GW, Ghelman B. Deep-vein thrombosis following total knee replacement: an analysis of six hundred and thirty-eight arthroplasties. J Bone Joint Surg Am. 1984;66:194-201.
5. Stamatakis JD, Kakkar W, Sagar S, Lawrence D, Nairn D, Bentley PG. Femoral vein thrombosis and total hip replacement. BMJ. 1977;2:223-225.
6. Harris WH, Salzman EW, Athanasoulis CA, Waltman AC, DeSanctis RW. Aspirin prophylaxis of venous thromboembolism after total hip replacement. N Engl J Med. 1977;297:1246-1249.
7. Johnson R, Carmichael JHE, Almond HGA, Loynes RP. Deep venous thrombosis following Charnley arthroplasty. Clin Orthop. 1978;132:24-30.
8. Nillius AS, Nylander G. Deep-vein thrombosis after total hip replacement: a clinical and phlebographic study. Br J Surg. 1979;66:324-326.
9. Evarts CM, Feil EJ. Prevention of thromboembolic disease after elective surgery of the hip. J Bone Joint Surg Am. 1971;53:1271-1280.
10. Hull R, Delmore T, Hirsh J, et al. Effectiveness of intermittent pulsatile elastic stockings for prevention of calf and thigh thrombosis in patients undergoing elective knee surgery. Thromb Res. 1979;16:37-45.
11. McKenna R, Galante J, Bachmann F, et al. Prevention of venous thromboembolism after total knee replacement by high-dose aspirin or intermittent calf and thigh compression. BMJ. 1980;1:514-517.
12. Stringer MD, Steadman CA, Hedges AR, Thomas EM, Morely TR, Kakkar VV. Deep-vein thrombosis after elective knee surgery: an incidence study in 312 patients. J Bone Joint Surg Br. 1989;71:492-497.
13. NIH Consensus Conference. Prevention of venous thrombosis and pulmonary embolism. JAMA. 1986;256:744-749.
14. Clagett PG, Salzman EW, Wheeler HB, Anderson FA, Levine MA. Prevention of venous thromboembolism. Chest. 1992;102(suppl):391S-407S.
15. Nicolaides AN, Arcelus J, Belcaro G, et al. Prevention of venous thromboembolism. Int Angiol. 1992;11:151-161.
16. Anderson DR, O'Brien BJ, Levine MM, et al. Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep-vein thrombosis after total hip arthroplasty. Ann Intern Med. 1993;119:1105-1112.
17. O'Brien BJ, Anderson DR, Goeree R. Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement. Can Med Assoc J. 1994;150:1083-1090.
18. Weinstein MC. Economic assessment of medical practices and technologies. Med Decis Making. 1981;1:309-330.
19. Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med. 1977;296:716-721.
20. How to read clinical journals, VII: to understand an economic evaluation. Can Med Assoc J. 1984;130:1428-1433, 1542-1549.
21. Drummond MF, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health-Care Programs. Oxford, England: Oxford University Press; 1987.
22. Eddy DM. Principles for making difficult decisions in difficult times. JAMA. 1994;271:1792-1798.
23. Hull R, Raskob G, Pineo G, et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med. 1993;329:1370-1376.
24. Hirsh J, Poller L. The international normalized ratio, a guide to understanding and correcting its problems. Arch Intern Med. 1994;154:282-288.
25. Hirsh J, Dalen JE, Deykin D, Poller L. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 1992;102 (suppl):312S-326S.
26. Hull R, Raskob G, Gent M, et al. Effectiveness of intermittent pneumatic leg compression for preventing deep-vein thrombosis after total hip replacement. JAMA. 1990;263:2313-2317.
27. Rabinov K, Paulin S. Roentgen diagnosis of venous thrombosis in the leg. Arch Surg. 1972;104:134-144.
28. Hull R, Delmore T, Genton E, et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med. 1979;301:855-858.
29. Rajhu R, Gafni A, Levine M, Hirsh J, Gent M. Very low-dose warfarin prophylaxis to prevent thromboembolism in women with metastatic breast cancer receiving chemotherapy: an economic evaluation. J Clin Oncol. 1995;13:42-46.
30. Simon G, Wagner E, Vonkorff M. Cost-effectiveness comparisons using 'real world' randomized trials: the case of new antidepressant drugs. J Clin Epidemiol. 1995;48:363-373.
31. Menzin J, Colditz GA, Regan MN, Richner RE, Oster G. Cost-effectiveness of enoxaparin versus low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery. Arch Intern Med. 1995;155:757-764.
32. Imperiale TF, Speroff T. A meta-analysis of methods to prevent venous thromboembolism following total hip replacement. JAMA. 1994;271:1880-1885.
33. Salzman EW, Davies GC. Prophylaxis of venous thromboembolism: analysis of cost-effectiveness. Ann Surg. 1980;191:207-218.
34. Hull R, Hirsh J, Sackett DL, Stoddart G. Cost-effectiveness of primary and secondary prevention of fatal pulmonary embolism in high-risk surgical patients. Can Med Assoc J. 1982;127:990-995.
35. Oster G, Tuden RL, Coldiz GA. A cost-effectiveness analysis of prophylaxis against deep-vein thrombosis in major orthopedic surgery. JAMA. 1987;257:203-208.
36. Hillman AL, Eisenberg JM, Pauly MV. et al. Sounding board: avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. N Engl J Med. 1991;324:1362-1365.
37. Kassirer JP, Angell M. The journal's policy on cost-effectiveness analyses. N Engl J Med. 1994;331:669-670,
38. Harenberg J, Wurzner B, Zimmermann R, Schettler G. Bioavailability and antagonization of the low molecular weight heparin CY 216 in man. Thromb Res. 1986;44:549-554.
39. Nightingale SL. Appropriate use of low-molecular-weight heparins (LMWHs). JAMA. 1993;270:1672.
40. Young E, Wells P, Holloway S, Hirsh J. Ex-vivo and in-vitro evidence that low-molecular-weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemost. 1994;71:300-304.